Analysts Issue Forecasts for Oncobiologics FY2026 Earnings

Oncobiologics, Inc. (NASDAQ:OTLK) – Investment analysts at Brookline Capital Markets boosted their FY2026 EPS estimates for shares of Oncobiologics in a research note issued to investors on Tuesday, August 18th. Brookline Capital Markets analyst K. Dolliver now expects that the company will earn ($0.42) per share for the year, up from their previous estimate of ($0.50). The consensus estimate for Oncobiologics’ current full-year earnings is ($0.49) per share. Brookline Capital Markets also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.07) EPS, Q4 2027 earnings at $0.05 EPS and FY2027 earnings at ($0.06) EPS.

Oncobiologics (NASDAQ:OTLK) last released its earnings results on Friday, August 14th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.97 million.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings upgraded shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. Wall Street Zen lowered Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Ascendiant Capital Markets raised their price target on Oncobiologics from $6.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 11th. BTIG Research restated a “buy” rating and issued a $4.00 price objective on shares of Oncobiologics in a research report on Friday, August 14th. Finally, HC Wainwright upped their price objective on Oncobiologics to $1.60 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $4.65.

Oncobiologics Price Performance

Shares of NASDAQ OTLK opened at $0.68 on Friday. The firm has a fifty day moving average price of $1.30 and a 200-day moving average price of $0.71. The stock has a market cap of $100.49 million, a PE ratio of -0.88 and a beta of 0.82. Oncobiologics has a 1 year low of $0.16 and a 1 year high of $3.39.

Insider Buying and Selling at Oncobiologics

In related news, Director Ghiath M. Sukhtian bought 8,539,709 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was purchased at an average price of $0.59 per share, for a total transaction of $5,038,428.31. Following the completion of the transaction, the director owned 22,092,068 shares in the company, valued at $13,034,320.12. The trade was a 63.01% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Faisal Ghiath Sukhtian bought 95,398 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were bought at an average cost of $1.05 per share, with a total value of $100,167.90. Following the completion of the purchase, the director directly owned 220,972 shares of the company’s stock, valued at $232,020.60. This represents a 75.97% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 11,189,359 shares of company stock worth $7,662,666 in the last three months. Insiders own 1.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after buying an additional 21,941 shares in the last quarter. AQR Capital Management LLC boosted its stake in Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after buying an additional 44,063 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.